BACKGROUND: Aspirin desensitization followed by daily aspirin provides therapeutic benefits to patients with aspirin-exacerbated respiratory disease (AERD). It is not well understood how eicosanoid levels change during aspirin treatment. OBJECTIVE: To investigate associations between clinical outcomes of aspirin treatment and plasma eicosanoid levels in patients with AERD. METHODS: Thirty-nine patients with AERD were offered aspirin treatment (650 mg twice daily) for 4 weeks. Respiratory parameters and plasma levels of multiple eicosanoids were recorded at baseline and after 4 weeks of aspirin therapy using the Asthma Control Test and Rhinoconjunctivitis Quality of Life Questionnaire. Respiratory function was evaluated using the FEV1 and nasal inspiratory peak flow. RESULTS: After aspirin treatment, respiratory symptoms improved in 16 patients, worsened in 12 patients, and did not change in 4 patients. Seven patients were unable to complete the desensitization protocol. Patients with symptom improvement had higher baseline plasma 15-hydroxyeicosatetraenoic acid (15-HETE) levels than did patients with symptom worsening: 7006 pg/mL (interquartile range, 6056-8688 pg/mL) versus 4800 pg/mL (interquartile range, 4238-5575 pg/mL), P = .0005. Baseline 15-HETE plasma levels positively correlated with the change in Asthma Control Test score (r = 0.61; P = .001) and in FEV1 after 4 weeks of aspirin treatment (r = 0.49; P = .01). It inversely correlated with Rhinoconjunctivitis Quality of Life Questionnaire score (r = -0.58; P = .002). Black and Latino patients were more likely to have symptom worsening on aspirin or fail to complete the initial desensitization than white, non-Latino patients (P = .02). CONCLUSIONS: In patients with AERD, low baseline 15-HETE plasma levels and black or Latino ethnicity are associated with worsening of respiratory symptoms during aspirin treatment.
BACKGROUND:Aspirin desensitization followed by daily aspirin provides therapeutic benefits to patients with aspirin-exacerbated respiratory disease (AERD). It is not well understood how eicosanoid levels change during aspirin treatment. OBJECTIVE: To investigate associations between clinical outcomes of aspirin treatment and plasma eicosanoid levels in patients with AERD. METHODS: Thirty-nine patients with AERD were offered aspirin treatment (650 mg twice daily) for 4 weeks. Respiratory parameters and plasma levels of multiple eicosanoids were recorded at baseline and after 4 weeks of aspirin therapy using the Asthma Control Test and Rhinoconjunctivitis Quality of Life Questionnaire. Respiratory function was evaluated using the FEV1 and nasal inspiratory peak flow. RESULTS: After aspirin treatment, respiratory symptoms improved in 16 patients, worsened in 12 patients, and did not change in 4 patients. Seven patients were unable to complete the desensitization protocol. Patients with symptom improvement had higher baseline plasma 15-hydroxyeicosatetraenoic acid (15-HETE) levels than did patients with symptom worsening: 7006 pg/mL (interquartile range, 6056-8688 pg/mL) versus 4800 pg/mL (interquartile range, 4238-5575 pg/mL), P = .0005. Baseline 15-HETE plasma levels positively correlated with the change in Asthma Control Test score (r = 0.61; P = .001) and in FEV1 after 4 weeks of aspirin treatment (r = 0.49; P = .01). It inversely correlated with Rhinoconjunctivitis Quality of Life Questionnaire score (r = -0.58; P = .002). Black and Latino patients were more likely to have symptom worsening on aspirin or fail to complete the initial desensitization than white, non-Latinopatients (P = .02). CONCLUSIONS: In patients with AERD, low baseline 15-HETE plasma levels and black or Latino ethnicity are associated with worsening of respiratory symptoms during aspirin treatment.
Authors: Eric Macy; Jonathan A Bernstein; Mariana C Castells; Sandra M Gawchik; Tak H Lee; Russell A Settipane; Ronald A Simon; Jeffrey Wald; Katharine M Woessner Journal: Ann Allergy Asthma Immunol Date: 2007-02 Impact factor: 6.347
Authors: Maria Pino-Yanes; Neeta Thakur; Christopher R Gignoux; Joshua M Galanter; Lindsey A Roth; Celeste Eng; Katherine K Nishimura; Sam S Oh; Hita Vora; Scott Huntsman; Elizabeth A Nguyen; Donglei Hu; Katherine A Drake; David V Conti; Andres Moreno-Estrada; Karla Sandoval; Cheryl A Winkler; Luisa N Borrell; Fred Lurmann; Talat S Islam; Adam Davis; Harold J Farber; Kelley Meade; Pedro C Avila; Denise Serebrisky; Kirsten Bibbins-Domingo; Michael A Lenoir; Jean G Ford; Emerita Brigino-Buenaventura; William Rodriguez-Cintron; Shannon M Thyne; Saunak Sen; Jose R Rodriguez-Santana; Carlos D Bustamante; L Keoki Williams; Frank D Gilliland; W James Gauderman; Rajesh Kumar; Dara G Torgerson; Esteban G Burchard Journal: J Allergy Clin Immunol Date: 2014-10-06 Impact factor: 10.793
Authors: Elina Jerschow; Matthew L Edin; Yuling Chi; Beth Hurst; Waleed M Abuzeid; Nadeem A Akbar; Marc Gibber; Marvin P Fried; Weiguo Han; Teresa Pelletier; Zhen Ren; Taha Keskin; Gigia Roizen; Fred B Lih; Artiom Gruzdev; J Alyce Bradbury; Victor Schuster; Simon Spivack; David Rosenstreich; Darryl C Zeldin Journal: J Allergy Clin Immunol Pract Date: 2018-12-21
Authors: Whitney W Stevens; Elina Jerschow; Alan P Baptist; Larry Borish; John V Bosso; Kathleen M Buchheit; Katherine N Cahill; Paloma Campo; Seong H Cho; Anjeni Keswani; Joshua M Levy; Anil Nanda; Tanya M Laidlaw; Andrew A White Journal: J Allergy Clin Immunol Date: 2020-12-09 Impact factor: 10.793
Authors: Whitney W Stevens; Anna G Staudacher; Kathryn E Hulse; Roderick G Carter; Deborah R Winter; Hiam Abdala-Valencia; Atsushi Kato; Lydia Suh; James E Norton; Julia H Huang; Anju T Peters; Leslie C Grammer; Caroline P E Price; David B Conley; Stephanie Shintani-Smith; Bruce K Tan; Kevin C Welch; Robert C Kern; Robert P Schleimer Journal: J Allergy Clin Immunol Date: 2020-05-01 Impact factor: 10.793